GlobeNewswire

Komet Reports 185 and 149.6 g/t Au from Grab Samples within the Guiro Mine

Dela

UEBEC CITY, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Komet Resources Inc. ("Komet" or the "Company") is pleased to announce a gold discovery 4km from the Guiro mine and the development of a new unmined shoot at the mine.

New Gold Zone

Komet geologists' verification of three 40m deep gold diggers' shafts, located about 4km northeast of the Guiro mine, revealed a quartz vein with a true width of 1.5m, oriented east-west, with a northward dip of 60 degrees. The vein has the same mineralogical composition and the same host rock limonitic alteration from weathering as the Guiro mine vein.

Sampling was carried out by Komet geologists in sealed bags directly from grab samples brought to surface by the gold diggers. The samples are random samples (3 grabs takes per composite sample). These grab samples are indicative but not representative of the grade of the gold structure.

Table of results of the grab samples:

Samples Description Au g/t
201 806 870 White quartz vein with black minerals bands, bearing limonite, hematite and pyrite 47.0
201 806 871 White quartz vein with black minerals bands, bearing limonite, hematite and pyrite 7.08
201 806 872 White quartz vein with black minerals bands, bearing limonite, hematite and pyrite with rare banded hematite 13.9
201 806 873 White quartz vein with hematitic alteration and disseminated hematite and pyrite 12.4
201 806 874 White quartz vein with hematite stringers with disseminated limonite and pyrite 9.89

New underground zone at the Guiro mine.

During the development in the western sector of the mine (see the October 23, 2017 press release), the Level 3 west gallery intercepted the junction where the 210/80 oriented shear cuts the Guiro vein (270/60).

In this sector the Guiro vein is hardly perceptible due to the shear that displaced the main structure. However, the operators noted the presence of thin centimetric quartz veins with gold mineralization, grading up to 120 g/t over 1.2m obtained from jackleg drill holes.

Table of the best results over 1.2m (true width) from jackleg drill holes:

Samples Au g/t
201 706 564 120.0
201 706 574 10.1
201 706 575 31.8
201 706 581 110.0

In order to better characterize this zone, several grab samples were taken from the roof, the wall and the sludge surrounding these thin chloritized white-pink quartz veins.

Summary of the best results of the grab samples:

Samples Au g/t
201 706 611 72.5
201 706 612 47.0
201 706 614 17.0
201 706 615 22.7
201 706 616 11.7
201 706 617 14.7
201 706 618 149.6
201 706 621 17.6
201 706 646 13.4
201 706 647 82.7
201 706 650 63.1
201 706 651 60.3
201 706 635 12.6
201 706 641 27.7
201 706 642 26.8

 

Samples Au g/t
201 706 655 26.9
201 706 658 185.0
201 706 661 13.5
201 706 667 10.5
201 706 668 11.6
201 706 669 52.3
201 706 670 12.5
201 706 672 67.4
201 706 677 12.6
201 706 680 50.6
201 706 684 16.5
201 706 687 13.9
201 706 692 16.5
201 706 693 14.5

The chimney to which the current development of level 3 is oriented, theoretically lies 25m farther west and has already been intercepted by the Gu2015dd04, 06, 32 and 35 diamond drill holes who show metric grades reaching 31.1g/t Au (see the September 10, 2015, press release for more details).

Table of the survey intercepting the chimney:

Survey From (m) To (m) g/t Au Span (m) True width (m)
Gu2015dd04 125.33 127.28 5.81 1.95 1.69
Gu2015dd06 80.60 83.40 2.05 2.80 2.42
Gu2015dd32 149.00 149.66 8.73 0.66 0.57
Gu2015dd35 105.45 106.80 31.1 1.35 1.17

This chimney is at least 50m wide at level 3 and continues to level 2 and 4 and should have, between these levels, a 60x50x2m size.

Guiro Mine Exploration

The sinistral offset of the Guiro structure, along the 210-degree shear in the west section of the mine, implies that this type of displacement might be present in the eastern sector, involving the displacement of the Guiro vein to the north and thus opening up new exploration targets northeast of the Guiro mine.

Mr André Gagné, president and CEO declare: "After a discovery south to the Guiro vein (see the may 25, 2017 press release), we now have a new vein to the north which is also similar to the Guiro vein. The exploration activities will hence be intensified in the next few weeks; it appears that the historical exploration data is getting confirmed."

The grab samples assays reported were obtained by standard 30 grams fire-assaying-AA finish or gravimetric finish at the Company's mine site laboratory. Quality Assurance/Quality Control and interpretation of results is performed by qualified persons employing a QA/QC program consistent with NI 43-101 and industry best practices, including the introduction of standards or blanks with every batch of 3 samples analyzed.

The diamond drill holes samples from 2015 were analyzed by the SGS Lab in Ouagadougou using fire assay followed by atomic absorption spectrometry.

More information about the corporation is available at: http://kometgold.com.

Investors relations and information: André Gagné, President and CEO 581-300-1666 / a.gagne@kometgold.com  / Skype: andregagne11

Jacques Marchand, P.Eng. P.Geo., is the Qualified Person who has reviewed this news release and is responsible for the geological information presented herein.

Forward-Looking Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute "forward-looking information" or "forward-looking statements" as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet's control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavorable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet's management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ccdd8280-c01e-4a86-a03b-ce1c316c11b1




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Komet Resources Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum